
Shaping Regulatory Strategy and Enabling Global Drug Development
At Shionogi, we are committed to improving global health through innovation, collaboration and scientific excellence. As our European development portfolio continues to grow, we are strengthening our regulatory capabilities to support successful product development and approvals across multiple therapeutic areas.
We are now seeking an Associate Director/Director, CMC Regulatory Affairs to lead strategic and operational regulatory activities across our development portfolio. This is a pivotal role with responsibility for defining CMC regulatory strategies, supporting global submissions and ensuring successful lifecycle management of products across the EU and beyond.
Why Join Shionogi?
Shionogi offers a purpose-driven, agile environment where individuals are empowered to make a meaningful impact. This role provides high visibility across global development teams, close collaboration with senior leadership, and the opportunity to influence regulatory strategy across multiple programmes and markets.
About the Role
As Associate Director/Director, CMC Regulatory Affairs, you will lead and oversee CMC regulatory strategy and execution across assigned products and projects This is a global role and therefore will allow the successful applicant to expand their knowledge from a core European focus. The role supports both projects in the development setting as well as lifecycle activities for approved products
Key responsibilities include:
What Are We Looking For?
We are looking for a Regulatory CMC scientist who can operate effectively in a complex and evolving global environment, balancing scientific, regulatory and business priorities.
You will bring:
Join Us
Join Shionogi and play a defining role in shaping regulatory strategy and enabling the successful development and approval of innovative medicines. If you are motivated by scientific excellence, global collaboration and making a meaningful impact in healthcare, we would welcome your application.

Since 1878, we have been committed to developing new treatments to improve patients' lives worldwide. We are helping to address global health challenges such as antimicrobial resistance and COVID-19.
Since the 1950s, we have discovered and introduced several novel antibiotics, as well as innovative medications for HIV and influenza. Today, we are developing an investigational oral antiviral for COVID-19 and advancing clinical programs in Fragile X syndrome, acute ischemic stroke as well metabolic disorders and oncology.
Our team is driven to impact patient lives. Our partnerships with industry, government agencies, biotech companies and academia help to advance science with the urgency that today's health challenges demand. Through a combination of in-house discovery and strategic partnerships, we continue to deliver firsts for patients in the U.S. and worldwide.
See our community guidelines: https://bit.ly/4n3Jhe4